Marker Therapeut - MRKR STOCK NEWS

Marker Therapeutics, Inc. (NASDAQ:MRKR) announced that President and CEO Peter L. Hoang will present at the Virtual Oppenheimer 31st Annual Healthcare Conference on March 17, 2021, at 3:10 p.m. ET. This clinical-stage immuno-oncology company focuses on developing next-generation T cell-based immunotherapies for hematological malignancies and solid tumors. A live webcast of the presentation will be accessible on Marker’s website, with a replay available afterwards.

Marker Therapeutics, Inc. (Nasdaq: MRKR) has announced the pricing of an underwritten public offering of 28,572,000 shares at $1.75 each, aiming to raise approximately $50 million before expenses. A 30-day option for underwriters to purchase an additional 4,285,800 shares has been granted. The offering, managed by Piper Sandler & Co. and Cantor Fitzgerald & Co., is expected to close around March 16, 2021, subject to customary conditions. This transaction is part of a shelf registration statement effective since June 25, 2019.

Marker Therapeutics, Inc. (Nasdaq: MRKR) announced a public offering of its common stock, with underwriters receiving a 30-day option to purchase additional shares. This offering is subject to market conditions and does not guarantee completion or specify terms. Piper Sandler & Co. is the sole book-running manager. The offering follows a shelf registration statement effective since June 25, 2019. Investors can access a preliminary prospectus through the SEC's website. Forward-looking statements about the offering's timing and details are included, reflecting potential risks.

Marker Therapeutics (MRKR) provided a corporate update and financial results for FY 2020, reporting a net loss of $28.7 million, up from $21.4 million in 2019. They launched a Phase 2 trial for AML, dosing their first patient in March 2021, and activated seven clinical sites, expecting up to 20 total. Their new cGMP manufacturing facility in Houston, designed for scalability, will support AML trials and future commercialization. Marker has $21.4 million in cash, funding operations into Q1 2022, but R&D expenses rose to $18.9 million.

Marker Therapeutics, Inc. (NASDAQ:MRKR) has announced the initiation of its Phase 2 trial for MT-401, a MultiTAA-specific T cell therapy aimed at treating patients with acute myeloid leukemia (AML) post-stem cell transplant. The trial, enrolling 160 patients across 20 cancer centers, will assess the therapy's effectiveness in both adjuvant and active disease settings. The primary goal for the adjuvant group is relapse-free survival, while the active group focuses on complete response rates. Topline results for the active group are expected in Q1 2022, addressing a significant unmet need for AML patients.

Marker Therapeutics (NASDAQ:MRKR) announced the completion of its cGMP manufacturing facility in Houston, TX, designed for scalable production of MultiTAA-specific T cell products. This facility will support the timely manufacture of MT-401, targeting acute myeloid leukemia (AML), particularly after the initiation of a Phase 2 study. The technology transfer process has begun, with operations expected in the first half of 2021. Marker’s MultiTAA platform is notable for its non-genetic modification approach, enhancing tumor-destroying capabilities while potentially allowing outpatient administration.

Marker Therapeutics (Nasdaq: MRKR) announced that the FDA has lifted the partial clinical hold on its Phase 2 trial for MT-401, a T cell therapy aimed at treating post-transplant acute myeloid leukemia (AML). This decision allows for the continued enrollment of patients in the trial, which evaluates MT-401's safety and efficacy compared to standard care. The trial, which includes approximately 120 patients in the adjuvant setting and 40 with active disease, aims to assess various survival metrics and remission rates. MT-401 has previously received Orphan Drug designation from the FDA.

Marker Therapeutics, Inc. (Nasdaq:MRKR) reported significant progress in its Phase 2 trial of MT-401 for acute myeloid leukemia (AML) in Q3 2020. The company enrolled its first patient for the safety lead-in portion and plans to activate approximately 20 clinical sites. Manufacturing improvements resulted in a 50% reduction in production time. Financially, Marker had cash and equivalents of $27.0 million, with a net loss of $7.4 million for the quarter, up from $5.5 million in Q3 2019. The new cGMP facility is on track for completion by year-end.

Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company, will host a conference call on November 9, 2020, at 5:00 p.m. Eastern Time to discuss its third quarter 2020 financial and operating results. The call will be accessible via the company’s website, and a replay will be available afterwards. Marker Therapeutics focuses on developing next-generation T cell-based immunotherapies for hematological and solid tumors, utilizing non-engineered, tumor-specific T cells to target multiple tumor antigens.